✦ LIBER ✦

35 ORAL Clinical attrition rates for kinase inhibitors in oncology

✍ Scribed by I. Walker; D.R. Newell

Book ID: 119599190
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 62 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)71967-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Worldwide Trends in Incidence Rates for

Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers

✍ Chaturvedi, A. K.; Anderson, W. F.; Lortet-Tieulent, J.; Curado, M. P.; Ferlay, 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 310 KB

62 Pre-clinical evaluation of LYS6KAKT1,

62 Pre-clinical evaluation of LYS6KAKT1, a novel, highly selective, orally bioavailable dual inhibitor of p70 S6 Kinase and AKT currently in phase I clinical trials for cancer

✍ S. Geeganage; L. Sams; S. Joseph; T. Shepherd; R. Dally; L. Brail; T. Wang; A. C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

610 Loss of the Tumor Suppressor Merlin

610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma

✍ Soria, J.C.; Plummer, R.; Ranson, M.; Gan, H.; Arkenau, H.T.; Zalcman, G.; Blagd 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Uracil/tegafur plus oral leucovorin does

Uracil/tegafur plus oral leucovorin does not affect survival rates but may be better tolerated than standard fluorouracil and leucovorin for previously untreated metastatic colorectal cancer: Abstracted from: Douillard J, Hoff P, Skillings J et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2002; 20: 3605–16.

✍ Borut Stabuc 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 82 KB